Prostate cancer: An evolving paradigm

Journal of Endourology

Volumn 24, Issue 5, 2010, Pages 805-809

  Caso, Jorge R ^a   Mouraviev, Vladimir ^a   Tsivian, Matvey ^a   Polascik, Thomas J ^a   Moul, Judd W ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CRYOSURGERY; EXTERNAL BEAM RADIOTHERAPY; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; REVIEW; TRANSRECTAL ULTRASONOGRAPHY;

HUMANS; MALE; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 77952554715     PISSN: 08927790     EISSN: None     Source Type: Journal    
DOI: 10.1089/end.2009.0539     Document Type: Review

References (40)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
2. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-1161.
3. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostatespecific antigen-based screening. JAMA 1993;270:948-954.
4. Jhaveri FM, Klein EA, Kupelian PA, et al. Declining rates of extracapsular extension after radical prostatectomy: Evidence for continued stage migration. J Clin Oncol 1999;17: 3167-3172.
5. Ung JO, Richie JP, Chen MH, et al. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology 2002;60: 458-463.
6. Hernandez DJ, Nielsen ME, Han M, Partin AW. Contemporary evaluation of the D'amico risk classification of prostate cancer. Urology 2007;70:931-935.
7. Desireddi NV, Roehl KA, Loeb S, et al. Improved stage and grade-specific progression-free survival rates after radical prostatectomy in the PSA era. Urology 2007;70:950-955.
8. Polascik TJ, Mayes JM, Sun L, et al. Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: Implications for unilateral ablative therapy. Prostate 2008;68: 1380-1386.
9. Cooperberg MR, Lubeck DP, Meng MV, et al. The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management. J Clin Oncol 2004;22:2141-2149.
10. Dong F, Reuther AM, Magi-Galluzzi C, et al. Pathologic stage migration has slowed in the late PSA era. Urology 2007;70: 839-842.
11. Wood HM, Reuther AM, Gilligan TD, et al. Rates of biochemical remission remain higher in black men compared to white men after radical prostatectomy despite similar trends in prostate specific antigen induced stage migration. J Urol 2007;178:1271-1276.
12. Freedland SJ, Presti JC Jr, Amling CL, et al. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology 2003;61:736-741.
13. Paquette EL, Sun L, Paquette LR, et al. Improved prostate cancer-specific survival and other disease parameters: Impact of prostate-specific antigen testing. Urology 2002;60: 756-759.
14. Smith EB, Frierson HF Jr, Mills SE, et al. Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: Is there evidence for systematic upgrading? Cancer 2002;94:2282-2287.
15. Tsivian M, Sun L, Mouraviev V, et al. Changes in Gleason score grading and their effect in predicting outcome after radical prostatectomy. Urology 2009;74:1090-1093.
16. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-974. (Pubitemid 28445094)
17. Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. J Clin Oncol 2005;23:8146-8151.
18. Dall'era MA, Hosang N, Konety B, et al. Sociodemographic predictors of prostate cancer risk category at diagnosis: Unique patterns of significant and insignificant disease. J Urol 2009;181:1622-1627.
19. Thompson IM, Ankerst DP. Prostate-specific antigen in the early detection of prostate cancer. CMAJ 2007;176:1853-1858.
20. http:==www.cua.org=guidelines-e.asp. Accessed August 1, 2009.
21. Beaulac JA, Fry RN, Onysko J. Lifetime and recent prostate specific antigen (PSA) screening of men for prostate cancer in Canada. Can J Public Health 2006;97:171-176.
22. Moore AL, Dimitropoulou P, Lane A, et al. Populationbased prostate-specific antigen testing in the UK leads to a stagemigration of prostate cancer. BJU Int 2009; June 22. E-pub ahead of print.
23. Bartsch G, Horninger W, Klocker H, et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001;58:417-424.
24. De Koning HJ, Liem MK, Baan CA, et al. Prostate cancer mortality reduction by screening: Power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial. Int J Cancer 2002;98:268-273.
25. Stephenson AJ, Kattan MW, Eastham JA, et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009;27:4300-4305.
26. Andriole GL, Crawford ED, Grubb III RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-1319.
27. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-1328.
28. Catalona WJ. Prostate-cancer screening. N Engl J Med 2009; 361:202,204-205.
29. Cooperberg MR, Carroll PR. Prostate-cancer screening. N Engl J Med 2009;361:203-205.
30. Van Leeuwen PJ, Connolly D, Gavin A, et al. Prostate cancer mortality in screen and clinically detected prostate cancer: Estimating the screening benefit. Eur J Cancer 2009; Oct 3. E-pub ahead of print.
31. Gallina A, Chun FK, Suardi N, et al. Comparison of stage migration patterns between Europe and the USA: An analysis of 11 350 men treated with radical prostatectomy for prostate cancer. BJU Int 2008;101:1513-1518.
32. Sartor AO, Hricak H, Wheeler TM, et al. Evaluating localized prostate cancer and identifying candidates for focal therapy. Urology 2008;72(suppl 6):S12-S24.
33. Mouraviev V,Mayes JM, Sun L, et al. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer 2007;110:906-910.
34. Miller DC, Gruber SB, Hollenbeck BK, et al. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst 2006;98:1134-1141.
35. Bill-Axelson A, Holmberg L, Filén F, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: The Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008;100:1144-1154.
36. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352:1977-1984. (Pubitemid 40638368)
37. Johansson JE. Watchful waiting for early stage prostate cancer. Urology 1994;43:138-142.
38. Johansson JE, Andrén O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA 2004;291: 2713-2719.
39. Wong YN, Mitra N, Hudes G, et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA 2006;296:2683-2693.
40. Polascik TJ, Mouraviev V. Focal therapy for prostate cancer. Curr Opin Urol 2008;18:269-274.